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Obesitynowpresents oneofthebiggest healthproblemsofourtimes.Diet andexercise are best forbothprevention andtreatment;
unfortunately, both require much discipline and are diﬃcult to maintain. Medications oﬀer a possible adjunct, but their eﬀect is
modest,theyarelimited by sideeﬀects, andthe weightlosslastsonlyaslongasthedrug isbeingtaken,sinceassoonastreatment is
stopped, the weight is regained. Sibutramine, a sympathomimetic medication which was available for long-term treatment, is the
m o s tr e c e n to ft h ed r u g st ob ew i t h d r a w nf r o mt h em a r k e td u et os i d ee ﬀects; in this case it was anincreased risk of cardiovascular
events. This paper reviews those medications which are available for treatment of obesity, including many of those recently taken
oﬀ the market. It also discusses some of the newer treatments that are currently being investigated.
1.Introduction
Obesity has become one of the biggest health problems of
our times. The World Health Organization’s (WHO) latest
projections indicated that globally in 2005 approximately 1.6
billion adults were overweight and at least 400 millions were
obese.TheWHOfurtherprojectsthatby2015approximately
2.3 billion adults will be overweight and more than 700
million will be obese. At least 20 million children younger
than 5 years old were overweight in 2005 [1].
Although obesity has been labeled a disease for over 200
years [2], only recently has it been recognized as a condition
that warrants medical attention. This is especially true given
the mounting data on the correlation between obesity and
type 2 diabetes, hypertension, dyslipidemia, cardiovascular
disease, stroke, and depression. Obesity is associated with
osteoarthritis, obstructive sleep apnea, increased risk of
cancer, and nonalcoholic fatty liver disease. It is related to
a variety of other complications, such as gastrointestinal
reﬂuxdisease,gout,headache, cellulitis,chronic renalfailure,
hypogonadism, and erectile dysfunction, among others.
Moreover, obesity is associated with a reduced quality of
life and social stigmatization [3, 4]. Unfortunately, doctors
remain reluctant to bring up thetopicof obesity when seeing
patients in their clinic. Less than 50% of obese patients are
even advised to lose weight [5].
This low involvement on the part of the doctor may be
due, in part, to the fact that at this time there is still no magic
bullet for the treatment of obesity, and diet and exercise
continue to be the cornerstone of treatment. Given the frus-
trations doctors and patients face in achieving results by diet
and exercise, drug therapy oﬀers an attractive option, even
if the results are modest. Unfortunately, despite the frantic
search at the moment for pharmacotherapy, few options cur-
rently exist. In the last few years many drugs that have been
eﬀective weight loss medications have had to be withdrawn
from the market secondary to unacceptable side eﬀects.
Fen-Phen, which was marketed as a combination of two
drugs fenﬂuramine and phentermine, was removed from the
market in September 1997, after it was reported that it could
cause valvular heart disease and pulmonary hypertension
[6]. In 2000, phenylpropanolamine, an over-the-counter
weight loss drug, was found to be an independent risk factor
for hemorrhagic stroke in women [7]. The ﬁrst selective CB1
receptor blocker, Rimonabant, was never approved in the
USA, but was available in 56 countries from July 2006 to
January 2009, when it was withdrawn from the European
market due to the fact that it caused increased depression2 Journal of Obesity
and suicidal ideation [8]. More recently, in October 2010,
sibutramine, a centrally acting serotonin-norepinephrine
reuptake inhibitor structurally related to amphetamines, was
withdrawn from the market because of its association with
increased cardiovascular events and strokes [9].
This paper reviews those medications which are available
for treatment of obesity, including many of those recently
taken oﬀ the market. It will also discuss some of the newer
treatments that are currently being investigated. While bari-
atric surgery has been increasing in popularity, and certainly
oﬀersa powerful tool with which to treat obesity,it is beyond
the scope of this paper.
2.IndicationsforMedical Therapy
Obesity is deﬁned as a body mass index (BMI; calculated as
weight in kilograms divided by the square of height in
meters) of 30 or more. Clinical practice guidelines for the
pharmacologic and surgical management of obesity in pri-
mary care have been issued by the American College of
Physicians (ACP) [10]. These guidelines are based upon
the results of two meta-analyses [11, 12]a n dt h ee x i s t i n g
guidelines from the United States Preventive Services Task
Force.
The guidelines include ﬁve recommendations. (1) Coun-
sel all obese patients (BMI ≥ 30kg/m2)o nd i e t ,l i f e s t y l e ,
and goals for weight loss. (2) Pharmacologic therapy may be
oﬀered to those who have failed to achieve weight loss goals
through diet and exercise alone. (3) Pharmacologic options
include sibutramine, orlistat, phentermine, diethylpropion,
and two drugs that are not approved for obesity treatment,
ﬂuoxetine and bupropion. (4) Bariatric surgery should be
considered for patients with BMI ≥ 40kg/m2 who have
failed diet and exercise (with or without drug therapy)
and who have obesity-related comorbidities (hypertension,
impaired glucose tolerance, diabetes mellitus, dyslipidemia,
sleep apnea). (5) Bariatric surgery should be performed at
high-volume centers with experienced surgeons. The NIH
alsosuggeststhatweightlossdrugsapprovedbytheFoodand
DrugAdministration(FDA)forlong-termusecanbeusedor
for patients with a BMI of ≥27 accompanied by risk factors
ordiseases. Theserisk factors arehypertension, dyslipidemia,
coronary heart disease, type 2 diabetes, and sleep apnea [13].
These recommendations may possibly change soon, in light
of the new ﬁndings linking sibutramine to an increased rate
of cardiac events [9]. The NIH also suggests that adults with
aBMI> 35who haveseriouscomorbiditiessuch asdiabetes,
sleep apnea, obesity-related cardiomyopathy, or severe joint
disease may also be candidates for bariatric surgery [14].
3.GoalsofTherapy
Perhaps the most important aspect of starting pharmaco-
logical treatment for obesity is to set realistic goals. Given
the diﬃculties of dieting, it is nearly impossible to reach
thepatientsexpectations. Numerousstudieshaveshown that
obese individuals want to lose the equivalent of 25–35% of
their initial weight and expect to do so in approximately 1
year of treatment [15]. Dieters maintain these expectations
even when repeatedly informed that they are likely to lose
only 5–15% of initial weight, which is the size of the losses
typically induced by current behavioral and pharmacolog-
ical interventions [16]. These data illustrate the dramatic
disparity between patients’ expectations and professional
recommendations and the need to help patients accept more
modest weight loss outcomes. A realistic treatment goal is
usually the loss of 5–10% of initial body weight over a 6-
to 12-month period, followed by long-term maintenance
of reduced weight. The NIH guidelines recommend that
weight loss should exceed 2kg during the ﬁrst month of
drug therapy (1 pound per week), fall more than 5% below
baseline by three to six months, and remain at this level to
be considered eﬀective [17]. If this is not achieved, then the
dose should be adjusted or the medication discontinued.
Althoughweightlossisanimportanttreatmentoutcome,
a major goal of obesity management should be to improve
cardiovascular and metabolic risk factors in order to reduce
obesity-related morbidity and mortality. Modest weight loss
as low as 5% of initial body weight can lead to favorable
improvementsinbloodpressure,serumlipidconcentrations,
increased insulin sensitivity, and improved glucose levels
[18–21]. Patients who have impaired glucose tolerance, type
2 diabetes, or hypertension are the ones who beneﬁt the
most as far as improvement in cardiovascular risk factors
[22]. The ongoing Look AHEAD study, initiated in 1999, is
a 12-year prospective trial designed to determine whether
a 7% weight loss will reduce the occurrence of myocardial
infarctionandstrokeinoverweightpatientswhoalreadyhave
type 2 diabetes [23].
When starting pharmacological therapy it is important
that the patient understands that once the maximal thera-
peutic eﬀe c ti sa c h i e v e d ,w e i g h tl o s sp l a t e a u sa n dt h a tw h e n
drug therapy is discontinued, the weight is regained [17].
Because the body reduces its energy expenditure as it loses
weight, more and more eﬀort must be made to maintain
the weight loss [24]. Weight regain results from complex
interactions between multiple factors including physiologic,
environmental,andpsychologicalfactors.Physiologicfactors
include reduced metabolic rate, both resting and nonresting
[25, 26], and increased adipose tissue lipoprotein lipase
activity [27]. These counterregulatory mechanisms protect
against starvation by causing an increase in appetite and
a decrease in energy expenditure, making it very diﬃcult to
keep oﬀ t h ew e i g h tt h a tw a sl o s t .
Patients must also be made aware of the fact that the
data on the use of these medications is limited, given that
the longest trials for sibutramine have a duration of only two
years, and for orlistat a maximum of four years. The trials
for the remaining medications are even shorter. Therefore,
if there is a good response to the medication and the
patient wishes to continue, the decision should be a shared
discussion between the physician and patient.
4.ReviewofMedications
4.1. Orlistat-Lipase Inhibitor. Orlistat (Xenical) was ap-
proved in 1998 for use for more than 12 weeks, which is
considered a long-term use. It reduces dietary fat absorptionJournal of Obesity 3
by 30% by inhibiting pancreatic and gastric lipase [28].
Orlistat is available in 120mg capsules. The recommended
dose is 120mg three times daily. A lower dose (60mg),
whichisnotaseﬀective,isavailableover-the-counterinsome
countries, including the United States.
Three randomized, double-blind,placebo-controlled tri-
als of orlistat lasting two years have been published. These
showed that orlistat 120mg (three times/day), taken with an
appropriate diet, resulted in clinically signiﬁcant weight loss
and reduced weight regain when compared to placebo. The
orlistat group, on average, lost 10.2% versus placebo which
lost 6.1% of body weight (P<. 001) from randomization to
the end of the ﬁrst year. During the crossover portion of the
studyinthesecondyear,patientswho continuedwithorlistat
regained, on average, half as much weight as those patients
switched to placebo (P<. 001) [28–30].
Ina longerfour-year studyinvolving 3305obesepatients,
21% of whom had impaired glucose tolerance, orlistat led
to weight loss during the ﬁrst year of more than 11%
below baseline in the orlistat-treated group versus 6% in the
placebo-treated group [31]. Over the remaining years of the
trial, both groups regained weight, but overall, the orlistat-
treated patients were 6.9% below baseline, compared with
4.1% for those receiving placebo.
In a meta-analysis of 22 trials that included patients
with and without diabetes and reported data with 12-month
outcomes, the mean diﬀerence in weight loss due to orlistat
was −2.89kg (−3.51 to −2.27kg) [11]. With an average
placebo eﬀect of −5.5kg, this translates into an expected
loss of −8.83kg on average for patients who adhered to the
treatment for this long. Almost two-thirds of the subjects
completed the ﬁrst year of treatment. Weight loss at one
year varied from 5.5 to 6.6% of initial body weight in the
placebo groups and 8.5 to 10.2% in the orlistat groups. Also
in diabetic patients orlistat resulted in signiﬁcantly more
weight loss and a decrease in hemoglobin A1c at one year
than placebo [32–34]. In all the studies, the lowest body
weight was achieved during the ﬁrst year.
The moderate eﬀect on body weight is suﬃcient to
improve several metabolic parameters. In a multicenter trial,
as an example, serum total and LDL cholesterol concen-
trations both decreased by 4–11% in subjects treated with
a weight-maintaining diet plus 30 to 360mg of orlistat per
day for eight weeks [35]. Blood pressure was reduced by
1.8mmHg systolic and 1.6mmHg diastolic. A retrospective
analysis showed reductions in triglyceride and cholesterol
blood levels, improved oral glucose tolerance, and a fall in
systolic and diastolic blood pressure [30].
Themajorsideeﬀectsoforlistattherapyaregastrointesti-
nal, including intestinal cramps,ﬂ a t u s ,f e c a li n c o n t i n e n c e ,
oily spotting, and ﬂatus with discharge [34]. These occur in
15–30% of the patients and tend to occur early and to
subside as patients learn how to avoid high fat diets and
stick to the recommended intake of no more than 30% fat.
Levels of fat-soluble vitamins (A, D, E) and beta-carotene are
reportedly lowered by orlistat therapy, with vitamin D the
most frequently aﬀected; therefore it seems prudent to also
give a multivitamin supplement when prescribing orlistat
[34].
4.2. Sibutramine-Sympathomimetic Drug, Formerly Approved
for Long-Term Use. Sibutramine (Meridia, Reductil) was
ﬁrst developed as an antidepressant, and although it was
ineﬀective for this, it was found to reduce body weight and
appetite. It is a centrally acting noradrenaline and serotonin
reuptake inhibitor that enhances weight loss by increasing
satiety. It may also have a thermogenic eﬀect in human
beings, but this remains controversial. It is given as a 10mg
dose once daily, usually in the morning, and could be
increased to 15mg daily after 4 weeks if needed. It was
available from 1997 until October 2010. We will discuss the
side eﬀects that led to its withdrawal, but ﬁrst we will review
its eﬃcacy.
More than 10 prospective, randomized, controlled trials
of sibutramine lasting 6–24 months have supported its
eﬃcacy [11]. An analysis of three trials of at least 1-yr
duration shows that patients on sibutramine lost 4.3kg or
4.6% more weight than those taking placebo; 34% more
patients achieved at least 5% weight loss, and 15% more
patients achieved at least 10% weight loss in the sibutramine
arm compared with placebo [36]. The weight loss seems
to be dose dependent [37], and the extent of initial weight
l o s si ns u b j e c t st r e a t e dw i t hs i b u t r a m i n ep r e d i c t st h el o n g -
term response. In two diﬀerent weight maintenance trials
comparing sibutramine to placebo, more weight loss was
seen in the drug-treated patients (mean 5.2kg) while the
placebo group gained weight (mean 0.5kg) [38, 39].
There are beneﬁts to using sibutramine intermittently, as
was seen in a randomized, placebo-controlled trial lasting
52 weeks [39]. The patients received either continuous
treatment with sibutramine at 15mg/day for 1 year or si-
butramine with two 6-week periods when the drug was
withdrawn. During the periods when the drug was replaced
by placebo, there was a small regain in weight that was again
lost when the drug was resumed. At the end of the trial, the
continuous-therapy and intermittent-therapy groups had
lost the same amount of weight.
Another study highlights how much intense lifestyle
modiﬁcationcontributestothesuccessofmedicaltreatment.
In a 1-year randomized trial, 224 obese adults received sibu-
tramine alone, sibutramine plus brief individualized lifestyle
modiﬁcation (8–10 visits of 10–15min each), group lifestyle
modiﬁcation alone (30 sessions), or sibutramine plus 30
sessions of group lifestyle modiﬁcation [40]. All subjects
were prescribed a calorie-restricted diet of 1200 to 1500kcal
per day and the same exercise regimen. At one year, subjects
in the combined therapy group lost a mean of 12.1 ± 9.8kg,
while those receiving sibutramine alone, lifestyle modiﬁca-
tion alone, or sibutramine plus brief lifestyle intervention
counseling lost 5.0 ± 7.4kg,6.7 ± 7.9kg,and7.5 ± 8.0kg,
respectively.
A number of studies have demonstrated that obese
patients with diabetes also seemed to beneﬁt from sibu-
tramine therapy [41–44]. As an example, in a six-month
trial in patients with diabetes, those treated with sibutramine
lost weight and had a decline in hemoglobin A1C values,
but no change in blood pressure [42]. In a meta-analysis
of eight randomized trials in 1093 obese patients with type
2 diabetes, signiﬁcant decreases were noted in body weight,4 Journal of Obesity
waist circumference, fasting blood glucose, and HbA1C in
the sibutramine group compared to placebo. Other treat-
ment beneﬁts included decreased serum triglycerides and
increased HDL concentrations [44].
In all these trials weight loss is associated with improved
lipid proﬁles [41, 42, 44]; however, the data for blood pres-
sure has been conﬂicting. In many trials patients treated with
sibutramine had signiﬁcant, albeit small, changes in blood
pressure [45, 46], on average by 1 to 3mmHg. This includes
patientswithhypertensioncontrolledwithotheragents,such
as calcium-channel blockers with or without concomitant
thiazide treatment [47]. However, a large surveillance study
of 6360 patients suggested a signiﬁcant decrease in blood
pressure with sibutramine in obese hypertensive patients
[48].
The diﬀerent trials also show that a small, but signiﬁcant
increase in pulse rate is seen with sibutramine use. In
a systematic review of 29 trials, the mean increase in heart
rate with sibutramine was 3.76beats/min (95% conﬁdence
interval, 2.70–4.82beats/min) [47]. None of the antihyper-
tensive drugs, including beta-blockers, appear to prevent the
rise in pulse rate with sibutramine.
Uncertainties about the cardiovascular safety of sibu-
tramine led to the initiation of the randomized, double-
blind, placebo-controlled Sibutramine Cardiovascular Out-
comes Trial (SCOUTs), which is the longest and largest
study with sibutramine [49]. This recently published study
enrollednearly 10,000patientswhowerefollowedforamean
of 3.4 years. It was designed to determine the impact of
weight loss with sibutramine on cardiovascular problems in
a population already at high risk for cardiovascular disease,
with 60% of the patients having a history of cardiovascular
disease and diabetes. The primary endpoint was the time
from randomization to the ﬁrst occurrence of a primary
outcome event, which included nonfatal myocardial infarc-
tion, nonfatal stroke, resuscitation after cardiac arrest, or
cardiovascular death. All patients were ﬁrst in a 6-week
lead-in period with sibutramine, in which the mean weight
l o s sw a s2 . 6 k g .T h es u b j e c t sw e r et h e nr a n d o m i z e dt o
sibutramine or placebo. The subjects in the sibutramine
group then achieved a further weight loss of 1.7kg, while
the placebo group gained weight, an average of 0.7kg by
month 12. The mean blood pressure decreased in both
groups, with greater reductions in the placebo group than
in the sibutramine group (mean diﬀerence, 1.2/1.4mmHg).
The trial showed that the risk of a primary outcome
event was increased by 16% in the sibutramine group
as compared with the placebo group (hazard ratio, 1.16;
95% conﬁdence interval (CI), 1.03 to 1.31; P = .02),
with overall incidences of 11.4% and 10.0%, in the two
groups, respectively. The rates of cardiovascular death and
death from any cause were not increased. Due to these
ﬁndings, where the weight loss did not seem to outweigh
the cardiovascular risks, the European Medicines Agency
recommended the suspension of marketing authorizations
forsibutramine across the EU. Monthslater, dueto pressures
exerted by the FDA, Abbot Laboratories announced that
it too would withdraw sibutramine from the US market
[50].
4.3. Benzphetamine, Diethylpropion, Phendimetrazine, and
Phentermine-Sympathomimetic Drugs Approved for Short-
Term Treatment. Benzphetamine (Didrex), Diethylpropion
(Tenuate), Phendimetrazine (Bontril), Phentermine (Adi-
pex-P), and Mazindol (Mazanor, Sanorex) are approved for
use for a period of up to 12 weeks. They are all amphetamine
derivatives that lead to weight loss by suppressing appetite.
Like amphetamines, they are centrally acting medications
that increase blood pressure and pulse rate. Of these,
phentermine is the most frequently prescribed weight loss
medication [51]. Phentermine comes in 15mg, 30mg, and
37.5mg doses and should be given once daily. Tablets may
be divided in half, and dose may be given in 2 divided doses,
while avoiding late evening administration.
Phentermine administered continuously in a 36-week
double-blind trial in 108 women led to 12.2kg loss, versus
placebo which was 4.8kg [52]. Diethylpropion has been
around since the 1950s, but up until very recently it had
rarely been studied beyond 20 weeks. However, a recent
randomized double-blind placebo-controlled study lasting
for one year showed that diethylpropion was safe. In the
study, 69obese healthy adultsreceiveda hypocaloric dietand
were randomized to diethylpropion 50mg BID or placebo
for 6 months. After this period, all participants received
diethylpropion in an open-label extension for an additional
6 months. After 6 months, the diethylpropion group lost an
averageof9.8%(s.d.6.9%)ofinitialbodyweightversus3.2%
(3.7%) in the placebo group (P<. 0001). From baseline to
month 12, the mean weight loss produced by diethylpropion
was 10.6% (8.3%). Participants in the placebo group who
were switched to diethylpropion after 6 months lost an
average of 7.0% (7.7%) of initial body weight. The diﬀerence
between groups at month 12 was not signiﬁcant (P = .07).
There was no diﬀerencebetween the two groupswith respect
to cardiovascular and psychiatric side eﬀects [53].
Phentermine and diethylpropion have been shown to
reduce weight signiﬁcantly when used intermittently. In
a way, this means that they can be used as chronic medica-
tions, as long as they are used in alternating months, and
therefore still remaining within the short-term limitations
[52]. Phentermine and diethylpropion are classiﬁed by
the U.S. Drug Enforcement Agency as schedule IV drugs,
meaning that they have a very low potential for drug
abuse. Benzphetamine and phendimetrazine are schedule
III drugs, meaning that they have a slightly higher poten-




The increased weight associated with many commonly
prescribed antidiabetic medications such as insulin, sul-
fonylureas, and thiazolidinediones leads many doctors and
patients to resist intensifying therapy as needed [54]. Fortu-
nately not all medications cause weight gain, and recently
new medications have been introduced that actually cause
weight loss.Journal of Obesity 5
5.1. Metformin. Metformin (Glucophage) was ﬁrst investi-
gated for its eﬀects on weight loss in trials as early as 1969
[55], but though the results were promising, metformin
was put aside when the following year a trial comparing
metformin with fenﬂuramine showed that fenﬂuramine was
much more eﬀective. Since then, only 9 trials have evaluated
weight loss as a primary endpoint of metformin treatment.
All of these studies, sometimes combined with orlistat or
sibutramine, showed signiﬁcant weight reduction, but they
were short-term studies, consisting of no more than 50
patients each [56–59].
Metformin comes in doses of 500mg, 850mg, or
1000mg. Generally, clinically signiﬁcant responses are not
seen at doses <1500mg daily; however, a lower recommend-
ed starting dose and gradual increased dosage are recom-
mended to minimize gastrointestinal symptoms. Extended
release formulations are available.
There are few large randomized controlled trials eval-
uating the eﬀect of metformin on weight as a secondary
outcome.ThelargestoneistheDiabetesPreventionProgram
[60]. This was a large-scale trial involving 3234 patients with
impaired glucose tolerance, which primarily evaluated the
incidence of diabetes at the end of the treatment period
among patients treated with either metformin, standard
lifestyle intervention (placebo group), or intensive lifestyle
modiﬁcation. After an average of 2.8 years of follow-up, the
metformin-treated group lost2.5% oftheirbody weight over
placebo (P<. 001).
The BIGPRO (Biguanides and Prevention of the Risks
in Obesity) trial evaluated the relationship between insulin
resistance and cardiovascular disease by giving metformin
to insulin-resistant patients [61]. The preliminary stage was
reported in the BIGPRO1 trial, which randomized 324
patients to receive metformin 850mg daily or placebo. The
metformin-treated patients had a nonsigniﬁcant decrease
in weight after 1 year (−2kg in metformin versus −0.8kg
in placebo) (P<. 06 versus placebo). Signiﬁcant dif-
ferences were observed for systolic blood pressure, which
decreased considerably more with metformin versus placebo
(P<. 003), and for fasting plasma glucose and total
and LDL cholesterol, which decreased slightly with met-
formin, while increasing with placebo (P<. 04; P<
.02 for LDL cholesterol). There was also a (nonsigniﬁ-
cant) trend towards a greater reduction of diastolic blood
pressure in the metformin group (P<. 09), whereas
w e i g h t ,B M I ,w a i s t - t o - h i pr a t i o ,2 h P G ,f a s t i n ga n d2 -
h insulin, HDL cholesterol, triglycerides and ﬁbrinolytic
markers did not diﬀer between the two treatment groups
[62].
The most common side eﬀects of metformin are gas-
trointestinal, including a metallic taste in the mouth, mild
anorexia, nausea, abdominal discomfort, and soft bowel
movements, or diarrhea. Lactic acidosis is an uncommon
side eﬀect; however, it remains a concern because of the
high case fatality rate. Thus, metformin should not be
administered to individuals with predisposing factors for
developing lactic acidosis, such as those with impaired renal
function.
5.2. GLP-1 Agonists: Exenatide and Liraglutide. GLP-1 is
ahormonesecreted byLcellsin theterminalileumafterfood
intake. It decreases blood glucose by inhibiting glucagon
secretionandstimulatinginsulinsecretion.GLP-1alsodelays
gastric emptying, reduces caloric intake, and promotes
satiety. Exenatide (Byetta) is a GLP-1 receptor agonists that
shares 53% homology to GLP-1 and has a much longer half
life becauseitisresistant todipeptidyl peptidase-4- (DPP-4-)
mediated degradation. It is administered as a subcutaneous
injection twice daily. It is approved to treat type 2 diabetes
and produces similar eﬀects to GLP-1, reducing fasting
and postprandial glucose levels, decreasing HbA1c, slowing
gastric emptying, and decreasing food intake by about 19%.
In diabetic patients it has been shown to cause weight loss by
an average of 1.6kg without any change in lifestyle, diet, or
exercise [63].
Exenatide, available in preﬁlled syringes that hold
a month’s supply of either 5 or 10mcg doses, is administered
subcutaneously twicedaily immediately before orwithin one
hour of morning and evening meals [64]. Exenatide should
not be used in patients with severe renal impairment (creati-
nine clearance <30mL/min) or end-stage kidney disease.
A study that followed 314 overweight patients with
type 2 diabetes, the ﬁrst 30 weeks of which were double
blind, followed by an open-label observation to week 82,
showedprogressiveweightreductionin80%ofpatients,with
an average reduction of 4.4% body weight [65]. Recently
another study was published that assessed the eﬀects of
exenatide on body weight and glucose tolerance in 152
nondiabetic obese subjects with normal or impaired glucose
tolerance (IGT) or impaired fasting glucose(IFG) [66]. They
were randomized to receive exenatide or placebo, along with
lifestyle intervention, for 24 weeks. The exenatide-treated
subjectslost5.1±0.5kgfrombaseline versus1.6±0.5kgwith
placebo (P<. 001), with a placebo-subtracted diﬀerence in
percent weight reduction of −3.3% ± 0.5% (P<. 001). IGT
orIFG normalized in 77% and 56%ofexenatideand placebo
subjects, respectively. Exenatide oﬀers a good alternative for
weight loss, particularly in nondiabetic obese subjects with
glucose intolerance.
A once a week version of exenatide is currently being
tested, so far, only in diabetic patients. The DURATION-1
study evaluated the safety and eﬃcacy of treatment with the
exenatide once weekly (2mg) compared to exenatide twice
daily in 295 patients with type 2 diabetes. It appears that
once a week exenatide will be just as eﬀective as twice daily
injections, since at 52 weeks the A1c changes were similar
and theweight losswas similar −4.1kg(−5.3to −2.9kg)and
−4.5kg (−5.7 to −3.3kg) in the two groups [67].
T h em o s tc o m m o ns i d ee ﬀects of exenatide are predom-
inantly gastrointestinal. Nausea is a common adverse eﬀect,
but it is generally mild to moderate in intensity and wanes
with duration of therapy [68]. Nausea can be reduced with
dose titration. There have been 36 postmarketing reports
of acute pancreatitis in patients taking exenatide [69]. In
some cases, necrotizing or hemorrhagic pancreatitis was
reported, and fatalities occurred. There is insuﬃcient data to
determine the overall frequency of pancreatitis in exenatide6 Journal of Obesity
users, but overall it seems similar to the background rate in
patients with diabetes mellitus.
Liraglutide (Victoza) is another long-acting GLP-1 ana-
log with a 97% structural homology to human GLP-1. It is
available for use in the United States, Europe, and Japan for
the treatment of type 2 diabetes. The drug is administered
subcutaneously once daily. In diabetes trials, liraglutide was
associated with a signiﬁcant reduction in weight (2.0 to
2.5kg) when compared with placebo or glimepiride [70].
Likeexenatide,liraglutideisonlyavailableasaninjection,
in preﬁlled pens. The initial dose is 0.6mg once daily for one
week to reduce gastrointestinal side eﬀects [71]. After one
week, the dose should be increased to 1.2mg once daily for
one week. If blood glucoses remain above the goal range, the
dose can be increased to 1.8mg once daily.
Weight loss has also been studied in patients without
diabetes who received liraglutide. In the 20-week study, 564
obese individuals were randomized to one of four liraglutide
doses (1.2mg, 1.8mg, 2.4mg, or 3.0mg) or to placebo
administered once a day subcutaneously, or orlistat 120mg
three times a day orally [72]. All individuals had a 500kcal
per day energy-deﬁcit diet and increased their physical activ-
ity throughout the trial. Treatment with liraglutide led to
a sustained, dose-dependent weight loss that was signif-
icantly greater than that with placebo (all doses) and
signiﬁcant for orlistat at the doses of liraglutide of 2.4mg
and 3.0mg. Mean weight loss with liraglutide ranged from
4.8 to 7.2kg, depending on the dose. The weight loss
was accompanied by reductions in waist circumference,
systolic and diastolic blood pressure, and frequency of
both metabolic syndrome and prediabetes. Liraglutide was
generally well tolerated. However, as in other trials, nausea
and vomiting were more frequent with liraglutide than with
the other treatments, although these events were mostly of
mild or moderate intensity and transient, tending tooccur in
the ﬁrst four weeks.
5.3. Pramlintide. Pramlintide (Symlin) is an analogue of
amylin, a small peptide hormone that is released into the
bloodstream by the β-cells of the pancreas along with
insulin in response to nutrient stimuli. Amylin has been
shown to slow gastric emptying, reduce postprandial rises in
bloodglucoseconcentrations,and improvehemoglobinA1C
concentrations in both type 1 and type 2 diabetes patients. It
mustbegivenbysubcutaneousinjection,atamaximumdose
of 120 micrograms with each meal.
Pramlintide is associated with modest weight loss in
patients with type 1 diabetes. In one such trial, where 651
patients with type 1 diabetes were randomly assigned to
placebo or subcutaneous pramlintide in addition to their
insulin,weightdecreased0.4kginthepramlintidegroupand
increased by 0.8kg in the placebo group [73].
A few trials evaluating the eﬀects of pramlintide on
weight in adults with type 2 diabetes have been done. One
large double-blind, placebo-controlled trial lasting 52 weeks
found that patients treated with pramlintide 30μg, 75μg,
and 150μg 3 times daily experienced signiﬁcant weight loss
compared to placebo at weeks 13, 26, and 52. Patients
were included in this trial if they were on stable doses of
metformin and/or a sulfonylurea, which is noteworthy since
metformin is associated with weight loss and sulfonylureas
are associated with weight gain [74]. Another double-blind,
placebo-controlled trial conﬁrmed signiﬁcant weight loss at
52 weeks [75]. In this trial, only the highest dose of 120μg
BID treatment group had a sustained weight loss to week 52
(P<. 05 versus placebo), whereas in the 90μg BID treatment
group, the placebo-corrected treatment diﬀerence was no
longer signiﬁcant.
Pramlintide has also been evaluated for the treatment of
obesity in adults without diabetes. In two studies in obese
subjects pramlintide signiﬁcantly reduced 24-hr caloric
intake by ∼500–750kcal when compared to placebo and also
reduced caloric intake by 20% at a highly palatable fast-
food challenge [76]. In a 4-month, randomized, double-
blind, placebo-controlled, nonforced dose-escalation study
in which 88% of subjects escalated to the maximum dose
(240μg t.i.d.), pramlintide induced a placebo-corrected
reduction in weight of 3.7% (P<. 001), with 31% of
pramlintide-treated subjects achieving ≥5% weight loss
(versus 2% for placebo; P<. 001) [77].
A more comprehensive study assessing the long-term
weight loss eﬃcacy and safety of pramlintide at diﬀerent
dosing regimens was carried out in 411 obese subjects [78].
These were randomized to receive pramlintide in one of 7
arms: 120μg b.i.d.andt.i.d,240μg b.i.d.and t.i.d,and 360μg
b.i.d. and t.i.d. or placebo. All subjects received a lifestyle
intervention program. At 4 months, 77% opted to continue
preexisting treatment during an 8-month single-blind. At
month 4, mean weight loss from baseline in the pramlintide
arms ranged from 3.8 to 6.1kg compared with 2.8kg in
the placebo arm. By month 12, the initial weight loss was
regained in the placebo group but was maintained in all
but the 120-μg b.i.d. group. Nausea, the most common
adverse event with pramlintide in the 4-month study (9–
29% pramlintide versus 2% placebo), was generally mild





agent approved in the mid-1990s for the treatment of
refractory seizures in conjunction with other anticonvulsant
agents. While it was being studied, it was discovered that
the agent mitigated the weight gain often observed with
antidepressant treatment. A 6-month dose-ranging study
showed that it does so in a dose-dependent manner; the
mean percent weight loss was −2.6% in placebo-treated
subjects versus −6.3% in subjects treated with 192mg/d
topiramate for 24wk [79]. In a meta-analysis of six trials
which followed patients for an average of six-months, the
weight loss was 6.51% (4.77 to 8.25%) with a placebo eﬀect
of about 2.0% [11].
Signiﬁcant side eﬀects of topiramate included fatigue,
paresthesias, diﬃcultyconcentrating,andchangesintaste.In
addition, patients using topiramate are at risk for secondary
acute angle glaucoma during the ﬁrst month of therapy.Journal of Obesity 7
Topiramate is also associated with decreases in serum
bicarbonate and development of metabolic acidosis [80],
markedly lower urinary citrate excretion, and increased
urinary pH. These changes increase the propensity of
topiramate to form calcium phosphate stones [81]. The high
frequency of side eﬀects has led to the termination of phase
III trials, while an extended release formulation is being
developed by the manufacturer.
6.2. Zonisamide. Zonisamide (Zonegran) is another anti-
epilepticdrugapprovedbytheFDAin2000forthetreatment
of partial seizures in adults with epilepsy. Whereas the anti-
convulsant activity of zonisamide is believed to be related
to its sodium and calcium channel blocking activity [82],
the drug is also known to exert dose-dependent biphasic
dopaminergic[83]andserotonergic[84]activity.Weightloss
was noted in clinical trials for the treatment of epilepsy [85],
hence prompting a trial for obesity.
Only onerandomized controlled trial hasbeen donethus
far, in which 60 obese subjects on a calorie-restricted diet
were randomly assigned to zonisamide (100mg/d increasing
to 400 to 600mg/d) or placebo for 16 weeks [86]. Mean
weight loss in the zonisamide group was 6.6% compared
to 1% in the placebo group. In 37 subjects who elected to
continue in the trial for an additional 16 weeks, mean weight
loss was 9.6 and 1.6% in the zonisamide and placebo groups,
respectively (P<. 001). The most common side eﬀects of
zonisamide are cognitive eﬀects and fatigue and a small, but
signiﬁcant, increase in serum creatinine. Zonisamide is not
FDA-approved for the treatment of obesity.
7.AntidepressantMedicationsThatLeadto
Weight Loss
7.1. Bupropion. Bupropion is a norepinephrine and do-
pamine reuptake inhibitor that is approved for treating
depression and smoking cessation. Bupropion seems to have
aw e i g h t - n e u t r a le ﬀect for most depressed individuals of
normal weight. However, controlled trials with depressed
individuals suggest that bupropion SR may be associated
w i t hw e i g h tl o s si no v e r w e i g h to ro b e s es u b j e c t s[ 87, 88]. In
addition, weight gain after treatment for smoking cessation
was less in bupropion SR-treated subjects than in placebo-
treated subjects [89].
In a 6-month, randomized, double-blind, placebo-
controlled trial 327 obese patients were treated with SR
bupropion (300 or 400mg/d) versus placebo [90]. Initial
body percent weight lost for subjects completing 24 weeks
was5.0%forplacebo,7.2%forbupropionSR300,and10.1%
forbupropion400mg/d.Compared with placebo,netweight
losses were 2.2% (P = .0468) and 5.1% (P<. 0001) for
bupropion SR 300 and 400mg/d, respectively. Also, there
was a 6-month extension where the weight loss was largely
maintained. The most common side eﬀects are dry mouth,
insomnia, headaches, and nausea. However, other serious
adverse events, such as seizures, occur in people who already
have a low threshold for seizures. The data is too scant to
recommend bupropion as a weight loss drug at this time.
7.2. Fluoxetine. Fluoxetine, a selective serotonin reuptake
inhibitor (SSRI) approved for the treatment of depression,
may also lead to weight loss. A clinical trial of ﬂuoxetine for
obesity included a total of 458 subjects who were randomly
assigned to ﬂuoxetine (60mg/d) or placebo. Fluoxetine
therapy (60mg/day) resulted in statistically signiﬁcantly
(P ≤ .05) greater mean weight loss than placebo at week 28.
Althoughsomepatientscontinuedtoloseweightthroughout
the 52-week therapy period, maximum mean weight loss
occurred at week 20. There was no treatment diﬀerence at 52
weeks, meaning that it would not be serving as a long-term
medication [91]. In a meta-analysis, trials of ﬂuoxetine as an
antiobesity drug at a dose of 60mg/d, which is three times
theusualdosefortreatment ofdepression,producedvariable
weight change ranging from 14.5kg lost to 0.40kg gained
[11].In summary, it can benoted that on averagemost of the
existing medications lead to about a 5% weight loss, with the
exception of the sympathomimetic drugs approved for short
term use (see Table 1 in supplementary material available
online at doi:10.1155/2011/636181).
8.New Drugsin Development
8.1. Leptin. The protein hormone leptin is produced by
adipose tissue and appears to signal adiposity and modulate
ingestive behavior [92, 93]. In mice and rare humans with
leptin deﬁciency, administration of physiological doses of
leptin decreases food intake and causes weight loss [94].
However, obese adults are found to have high levels of leptin
[95], so perhaps there is a state of leptin resistance. If that
resistance is overcome with even higher levels of leptin, then
perhaps it could lead to weight loss.
A randomized, double-blind, placebo-controlled, multi-
center, escalating dose cohort trial was conducted to deter-
mine the relationship betweenincreasing dosesof exogenous
leptin administration and weight loss. In one part of the
study 47 obese people on a calorie restricted diet were given
eitherplacebo orrecombinant leptin at escalating doses0.01,
0.03, 0.10, or 0.30mg/kg. By week 24 there was a dose-
dependent decrease in body weight, ranging from −1.3kg
in the placebo group to −7.1kg in the 0.30mg/kg group
(P = .01). No clinically signiﬁcant adverse eﬀects were
observed on major organ systems, but it was associated with
an unacceptable incidence of injection site reactions [96].
A possible use for leptin may be as an adjunctive
therapy for the maintenance of weight loss. The reductions
in energy expenditure and thyroid hormone concentrations
that occur with weight loss may be due to a decline in leptin
concentrations and may also hamper the ability to maintain
weight loss. These metabolic and hormonal changes are
reversed tothe preweight-reduced state afteradministrations
of low replacement dose leptin. This was seen in a small
proof-of-concept study carried out in 10 inpatient subjects
where leptin therapy prevented weight gain after signiﬁcant
weight loss, bypreventingtheweight loss-associated decrease
in energy expenditure [97].
8.2. Peptide YY. The gut hormone peptide YY (PYY) is
synthesized and cosecreted with GLP-1 by the L cells in the8 Journal of Obesity
small intestine. It suppresses appetite and decreases food
intake [98]. This was illustrated in a trial of obese and
lean adultsreceiving short-term intravenous infusion ofPYY
administration. Appetite and caloric intake decreased by
approximately 30% in both groups when the subjects were
oﬀeredabuﬀetmeal,and24hourcaloricintakewasreduced.
Obese subjects had signiﬁcantly lower fasting PYY levels
and levels correlated inversely with body mass index. These
observations suggest that PYY has an important regulatory
role in feeding behavior, potentially oﬀering a target for drug
development [99].
In contrast, in a 12-week trial, 133 obese patients were
randomly assigned to diet and exercise and either intranasal
PYY (200 or 600mcg three times daily before meals) or
placebo [100]. The group receiving 600microg t.i.d. could
notbeassessed because59%ofthepatientsdiscontinueddue
tonauseaandvomiting.Therewasnotstatisticallysigniﬁcant
diﬀerence between placebo and the 200mcg group.
8.3. Oxyntomodulin. Oxyntomodulin is a peptide produced
in L cells of the GI track from the proglucagon gene
product. It is released into the blood in response to food
ingestion and in proportion to meal calorie content [101].
Oxyntomodulin has been reported to reduce food intake
by 19.3% during an intravenous infusion administered to
normal-weight humans, an eﬀect that continues for >12h
after infusion [102].
In a randomized, double blind study oxyntomodulin or
saline was self-administered for 4 weeks, three times daily
before each meal. The volunteers were asked to maintain
their regular diet and level of physical exercise during the
study period. Body weight was reduced by 2.3 ± 0.4kg in
t h et r e a t m e n tg r o u po v e rt h es t u d yp e r i o dc o m p a r e dw i t h
0.5 ±0.5kg in the control group (P = .0106) [103].
8.4. Melanocortin-4 Receptor Agonists. The hypothalamic
melanocortin system appears to enhance energy expenditure
and suppress appetite. In a study in adults with normal
weight, intranasal administration of the MSH/ACTH4–10
core fragment of pro-opiomelanocortin for 6 weeks resulted
in a signiﬁcant reduction of body weight by 1.7kg [104].
However, a study of 23 overweight men who were given the
same compound for 12 weeks did not show any signiﬁcant
decrease in body weight or body fat when compared to
placebo [105].
8.5. Lorcaserin. Stimulation of speciﬁc central serotonin
receptors represents an eﬀective pharmacological mecha-
nism to suppress appetite. Serotonin and agonists that
activate serotonin 2C (5-HT2C) receptors promote feelings
ofsatiety,therebyreducingfoodintake[106,107].Lorcaserin
is a selective 5-hydroxytryptamine (serotonin) (5-HT) 2C
agonist currently in phase 3 clinicaltrials for treating obesity.
In a 12-week placebo-controlled randomized study of 333
obese individuals taking 10mg once a day, 15mg once a day,
or 10mg twice a day, lorcaserin was shown to be associated
with dose-dependent weight loss without instructed lifestyle
modiﬁcation; 1.8, 2.6, and 3.6kg of weight loss, respectively,
were observedoverthe12-week period comparedwith 0.3kg
with placebo [108]. Lorcaserin-treated subjects had reduced
plasma cholesterol, waist circumference, fasting glucose,
and serum uric acid. Lorcaserin has 7.5-fold selectivity for
5-HT2C receptors over 5-HT2A receptors and 11.6-fold
selectivity for 5-HT2C receptors over 5-HT2B receptors
[109]. In clinical trials, 5-HT2A receptor activation, which
may cause neuropsychiatric eﬀects, has not appeared to be
signiﬁcantly activated by the dosages used.
8.6. Tesofensine. Tesofensine is a sympathomimetic in the
family of sibutramine initially developed for the treatment
of Parkinson’s disease. Although its eﬃcacy was limited for
this application, study subjects were noted to experience
signiﬁcant weight loss by appetite suppression [110].
In a recent multidose dose-ranging trial, 203 obese
patients were randomly assigned to diﬀering doses of
tesofensine (0.25, 0.5, and 1.0mg) or placebo once daily
[111]. After 24 weeks, mean weight reduction was greater in
the tesofensine groups (−6.7, −11.3, −12.8kg, for the three
doses, resp.) compared with placebo (−2.2kg). Common
adverse events included dry mouth, nausea, abdominal
pain, and diarrhea. Heart rate was signiﬁcantly elevated
in all tesofensine groups (5 to 8 beats per min) (P =
.0001). The 0.25 dose and the 0.5mg dose did not show
any changes in blood pressure as compared to placebo;
however, the highest dose of tesofensine of 1.0mg daily was
associated with a signiﬁcant increase in systolic and diastolic
blood pressure (mean increase 6.8/5.8mmHg). Insomnia,
dry mouth, constipation, diarrhea, and dizziness were also
more common. The highest dose of tesofensine showed the
highest frequency of mood change. These mild increases in
heart rate or blood pressure may end up having clinical
signiﬁcance, as was recently seen in sibutramine.
9.CombinationTreatments
None of the single-agent drugs that have been approved or
appear closetoapproval has consistentlybeen able toachieve
a weight loss of more than approximately 10% of body
weight. The combination of phentermine and fenﬂuramine,
which was taken oﬀ the market in 1997, was able to achieve a
lossofapproximately15%ofbodyweight[112].Recognizing
the complex pathophysiology of obesity, recent eﬀorts have
focused on combination therapies. Using more than one
drug to treat obesity is similar to treating hypertension,
whereoftenseveraldrugsareneededtoreachthetargetgoals.
Surprisingly,thecombinationoforlistat andsibutramine
yielded disappointing results. In one trial of 34 obese women
who had already lost an average of11% of their initial weight
with sibutramine during the prior one year of treatment, the
addition of orlistat to the sibutramine for an additional four
months did not induce any further weight loss when com-
pared to sibutramine plusplacebo [113]. In a diﬀerent open-
label, randomized, 12-week trial, 86 overweight patients
received either orlistat 120mg three times a day, sibutramine
10mg/d, the combination of orlistat-sibutramine, or diet
[114]. After 12 weeks, sibutramine produced more weightJournal of Obesity 9
loss than orlistat alone. The addition of orlistat to sibu-
tramine did not signiﬁcantly enhance weight loss, similar to
the results of the ﬁrst trial.
A number of novel combination obesity treatments are
being investigated in clinical trials. These include phenter-
mine plus topiramate (Qnexa), bupropion plus naltrexone
(Contrave), zonisamide plus long-acting bupropion, topira-
mate and phentermine, and pramlintide plus leptin.
Three phase 3 trials evaluating phentermine plus top-
iramate (Qnexa) in over 4,500 patients as a treatment for
obesity were recently completed under a Special Protocol
Assessment by the U.S. FDA. Qnexa is currently under
review by the FDA for the treatment of obesity and is
not yet approved. EQUATE, the ﬁrst of the three phase 3
studies, evaluated 756 obese patients over 28 weeks at 32
sites. EQUIP and CONQUER were 56-week studies; EQUIP
evaluated 1,267 morbidly obese patients with or without
comorbidities, and CONQUER evaluated 2,487 overweight
and obese patients with at least two comorbid conditions
[115].
The combination of bupropion plus naltrexone (Con-
trave) is also showing promising eﬀects. Naltrexone, which
is used in the treatment of alcoholism, is not associated with
weight loss, and bupropron is associated with modest weight
loss, but the combination clearly leads to greater eﬀect. The
drug was tested in a 56-week clinical trial that enrolled
nearly 700 obese people. All study participants enrolled in an
intensive weight loss programthat includedcounseling, diet,
and exercise. Two-thirds of the study participants also took
Contrave. Participants stayed in the program for 56 weeks.
By the end, the placebo group, on a weight loss program,
lost over 5% of their body weight—11 to 16 pounds, while
the Contrave group lost 9.3% of their body weight—20 to
25 pounds. And more than 29% of them lost more than
15% of their body weight. The study had a drop-out rate
of over 40%, therefore diluting the eﬀect [115]. On March
31st 2010, Orexigen submitted a New Drug Application
(NDA)to the U.S. Food and Drug Administration (FDA) for
Contrave. Similar eﬀects were seen with the combination of
the long-acting anticonvulsant zonisamide with long-acting
bupropion, marketed under Empatic [115].
With the combination of the anticonvulsant topiramate
and phentermine in doses one quarter to one-half of those
typically used with both agents, weight loss again was seen,
with acceptable although deﬁnite side eﬀects, including
paresthesia in16–23%versus3%ofthoseonplaceboanddry
mouth in 13 and 19% versus none on placebo. An increase
in depression and other psychiatric issues were not reported,
although there was insomnia in 10–12% versus 6% [116].
In a 24-week study, less than 3% weight loss was seen
with pramlintide alone, but 11% weight loss was seen when
it was combined with either phentermine or sibutramine.
All patients also received lifestyle intervention. Elevations
from baseline in heart rate and diastolic blood pressure
were demonstrated in boththe pramlintide-sibutramine and
pramlintide-phentermine group. These results support the
potential of pramlintide-containing combination treatments
for obesity, but the blood pressure and heart rate changes
with sibutramine and phentermine remain a concern [117].
The combinations of pramlintide plus leptin are also
being studied. Pramlintide, in a dose 360 micrograms twice
dailydose,which ismuchhigherthanthe15–120microgram
three times daily usually used in diabetes and metreleptin
5mg twice daily showed that the agents alone result in
a 7% weight loss, but the combination of the two results in
a 13% weight loss in completers at 20 weeks [118]. Although
the rate of weight loss in the pramlintide-metreleptin arm
decreased over time, a plateau was not reached by the
end of the study. The most common side eﬀects seen
with pramlintide-metreleptin combination treatment were
injection site adverse events and nausea, which were mostly
mild to moderate and transient in nature.
10.Conclusion
Obesity now presents one of the biggest health problems of
our times. Diet and exercise are best for both prevention
and treatment; unfortunately, both require much discipline
and are diﬃcult to maintain. Medications oﬀer a possible
adjunct, but their eﬀect is modest, they are limited by
side eﬀects, and the weight loss lasts only as long as the
drug is being taken, since as soon as treatment is stopped,
the weight is regained. Sibutramine, a sympathomimetic
medication which was available for long-term treatment, is
the most recent of the drugs to be withdrawn from the
market due to side eﬀects; in this case it was an increased
risk of cardiovascular events. A number of other drugs
remain available, but learning more about the combination
of existing medications and new drug development will
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